Sequencing and Transitions for Advanced Renal Cell Carcinoma: Leveraging the Latest Tools  
and Managing Complications

Release Date: January 30, 2017
Last Reviewed: January 16, 2017
Expiration Date: January 30, 2018
Time to Complete Activity: 1.0 hour
*This activity expired for credit on January 30, 2018 and is no longer available for credit

Mayer N. Fishman, MD, PhD
Senior Member
Moffitt Cancer Center
Tampa, FL

Margaret “Peggy” Zuckerman, MS
Patient Advocate
Society for Participatory Medicine
Kure It
Action to Cure Kidney Cancer
Long Beach, CA

Steering Committee
Sumanta Kumar Pal, MD (Chair)
Assistant Professor, Co-Director
Kidney Cancer Program
City of Hope
Duarte, CA
Mayer N. Fishman, MD, PhD
Senior Member
Moffitt Cancer Center
Tampa, FL
Brian I. Rini, MD
Professor of Medicine
Cleveland Clinic
Taussig Cancer Institute
Cleveland, OH

Margaret “Peggy” Zuckerman, MS
Patient Advocate
Society for Participatory Medicine
Kure It
Action to Cure Kidney Cancer
Long Beach, CA

This activity is provided by Paradigm Medical Communications, LLC.  

In collaboration with the Kidney Cancer Association (KCA).
Target Audience
This activity has been designed to address the educational needs of medical oncologists, urologic oncologists, and urologists. It may also be of benefit to nurses, PAs, and other members of the multidisciplinary healthcare team who provide care for patients with advanced renal cell carcinoma.
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
  • Explain the mechanisms of action underlying the different classes of agents available for the treatment of advanced renal cell carcinoma.
  • Select optimal treatments for first-line, second-line, and third-line therapy for a patient with advanced renal cell carcinoma.
  • Outline management strategies for adverse events associated with treatments for advanced renal cell carcinoma.
Chapter 1: Introduction
Chapter 2: Mechanisms of Action of Current and Emerging Therapies: Why Targeting Different Pathways Is Necessary for the Treatment of RCC
Chapter 3: Selecting, Sequencing, and Transitioning among TKIs, mTOR Inhibitors, and Immunotherapies for Advanced RCC
Chapter 4: Evaluating and Managing Adverse Events for Agents with Different Mechanisms of Action
Chapter 5: Tying It All Together: Impact on Urology and Oncology Practices
Chapter 6: Q & A
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 Category 1 credit for completing this activity.
Disclosure of Commercial Support
This activity is supported by an educational grant from Pfizer Inc. 
Instructions for Participation
To receive a CME certificate of participation, you should:
  • Follow instructions to register or log in with your professional information and complete the pre-activity assessment.
  • View the online activity in its entirety.
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest.
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.
Hardware/Software Requirements
This certified CME activity is designed using HTML5 video and audio.
Supported Browsers:
For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
Technical Support: If you have any technical problems or playback issues email us at
In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

Mayer N. Fishman, MD, PhD
Grant/Research Support: Acceleron Pharma, Inc; Altor BioScience Corporation; Argos Therapeutics, Inc; Bristol-Myers Squibb Company; Eisai Co., Ltd; Exelixis, Inc; Genentech, Inc; Merck & Co., Inc; Pfizer Inc; Prometheus Laboratories Inc; Takeda Pharmaceuticals U.S.A., Inc
Speakers Bureau: Exelixis, Inc; Pfizer Inc
Margaret “Peggy” Zuckerman, MS
No financial relationships to disclose.

Steering Committee
Sumanta Kumar Pal, MD (Chair)
Retained Consultant: Bristol-Myers Squibb Company; Exelixis, Inc; Genentech, Inc; Novartis; Pfizer Inc
Speakers Bureau: Genentech, Inc
Brian I. Rini, MD
Retained Consultant: AstraZeneca; Pfizer Inc
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC is committed to protecting the privacy of those who participate in the activities (herein referred to as “website”) located at The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.